Premier Endpoint

Interviews

Interview with James Sapirstein, CEO at Contravir, on novel compounds against hepatitis B: TXL and CRV431

September 5, 2017 By Klara Czobor

KLARA CZOBOR: Can you talk about what TXL is and how it addresses the unmet need in the treatment of hepatitis B? JAMES SAPIRSTEIN: Well, TXL is a lipid conjugate of a drug that’s already available, a lipid conjugate of tenofovir. And basically, right now, it’s very early stage for hepatitis B. We know that […]

Interviews

Interview with James Sapirstein, CEO at Contravir, on Valnivudine treatment of herpes zoster and post-herpetic neuralgia (PHN)

August 29, 2017 By Klara Czobor

KLARA CZOBOR: Can you please provide us with a brief background about yourself and how you came to be the CEO of ContraVir Pharmaceuticals? JAMES SAPIRSTEIN: Okay. I’m a pharmacist with an MBA, and for my first 17 years in the industry, I worked in large pharmaceutical companies including Eli Lilly, Hoffmann-LaRoche, and Bristol-Myers Squibb, […]

Interviews

A Special Follow Up Interview with David Esposito of Armune BioScience

August 22, 2017 By Stephen Strudwick

Armune BioScience has developed the peer-reviewed and validated prostate-cancer-risk-assessment technology Apifiny®—a cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. We are delighted present a follow up interview with David Esposito, President and Chief Executive Officer at Armune BioScience, Kalamazoo, Michigan. Our original interview with […]

Interviews

Interview with Brady Granier, CEO at BioCorRx Inc. Part 3: B2-NTX, a new protocol specifically designed for battling opioid use disorder

August 15, 2017 By Stephen Strudwick

This is the final part of our 3-part interview series where we talk with Brady Granier, president and Chief Executive Officer, Director at BioCorRx, Inc, Anaheim, California about BioCorRx Recovery Program and B2-NTX, a new protocol specifically designed for battling opioid use disorder. KLARA CZOBOR: How does the BioCorRx Recovery Program improve upon the traditional modalities such as […]

Interviews

Interview with Brady Granier, CEO at BioCorRx Inc. Part 2: company goals and the promise of BICX101, a new long-lasting injectable naltrexone technology

August 8, 2017 By Stephen Strudwick

BioCorRx® is a leading edge healthcare solutions company focused on improving the lives of those struggling with alcohol and opioid addiction. In this second part of a 3-part interview with Brady Granier, president and Chief Executive Officer, Director at BioCorRx, Inc, Anaheim, California, we discuss the goals of BioCorRx and its two-pronged approach to the treatment of substance abuse […]

Interviews

Interview with Brady Granier, CEO at BioCorRx Inc. Part 1: use of medications to treat alcohol and opioid addiction

July 31, 2017 By Stephen Strudwick

Addiction is a powerful disorder that affects over 23 million people in the U.S.1 and costs an estimated $700 billion each year2. In this first part of a 3-part interview with Brady Granier, president and Chief Executive Officer, Director at BioCorRx, Inc, Anaheim, California, we discuss what made him leave his 11-year career with a major […]

Interviews

Interview with Randy Milby, CEO of Hillstream BioPharma Inc

May 31, 2017 By Stephen Strudwick

This is the second post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with Randy Milby, Chief Executive Officer at Hillstream BioPharma, Inc, Chester, New Jersey (http://www.hillstreambio.com). RANDY MILBY: I’ll start with how I founded the company, Hillstream Biopharma. Until […]

Interviews

Nicholas Vogelzang, MD: Unmet Needs in Oncology

October 24, 2016 By Stephen Strudwick

Klara Czobor: Our first question Dr. Vogelzang is what malignancy do you primarily treat in your practice? Dr. Vogelzang: Being a general oncologist in private practice, I get to treat many different malignancies. I primarily treat prostate, kidney, and bladder cancer. I also treat patients with testicular cancer and sarcoma, as well as smaller numbers […]

Interviews

Interview with David Esposito of Armune BioScience

October 20, 2016 By Stephen Strudwick

This is the first post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with David Esposito, President and Chief Executive Officer at Armune BioScience, Ann Arbor, Michigan. DAVID ESPOSITO: Armune BioScience is an early stage, medical diagnostics company started in […]